tirzepatide in mounjaro FDA Says Compounded Must Exit the Market Mounjaro (Tirzepatide) Prescribing Update –

The challenge in evaluating GLP-1 safety lies in disentangling drug effects from underlying disease risk

On the other hand, younger individuals (aged 1850) using GLP-1RA demonstrated a significantly higher composite risk compared to DPP-4i users (HR: 1.553, 95% CI: 1.3621.771) than those older than 50 years (HR: 1.174, 95% CI: 1.0971.256) (Additional file 2: Fig

Patients who maintain a protein-rich diet, stay hydrated, and engage in regular movement typically lose weight faster than those who rely solely on appetite suppression

Our five core pillars target the root causes of aging and disease to help you feel stronger, think clearer, and live better for longer

This reinforces the idea that weight management requires a multifaceted strategy

While blood pressure reduction contributes, other mechanisms are also involved